Merck Announces Appointment of Jennifer Zachary as General Counsel


March 20, 2018 4:05 pm ET

Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the appointment of Jennifer Zachary as general counsel,
effective April 16, 2018. Zachary will be responsible for Merck’s global
legal, security and aviation, and environmental, health and safety
organizations, and be a member of Merck’s Executive Committee. She
succeeds Michael J. Holston.

“We are delighted to welcome Jennifer as our new general counsel. Her
extensive experience across the biopharmaceutical industry makes her an
exceptional addition to our team,” said Kenneth C. Frazier, chairman and
chief executive officer, Merck.

Zachary is currently a partner at Covington & Burling in the firm’s
food, drug, and device practice group where she advises a wide range of
manufacturers and industry trade associations on FDA’s requirements for
the development, manufacture, and distribution of prescription and
over-the-counter drugs, biologics, and medical devices. Zachary began
her career in FDA’s Office of Chief Counsel, where she served as an
Associate Chief Counsel for Enforcement from 2005 to 2011. Zachary also
served as a Special Assistant U.S. Attorney in the Civil Division of the
U.S. Attorney’s Office for the District of Columbia.

“I’m honored and excited to have the opportunity to join Merck’s
Executive Committee,” said Zachary. “I have long admired Merck for its
steadfast commitment to its core values and I look forward to
contributing to the company’s long-term success.”

About Merck

For more than a century, Merck, a leading global biopharmaceutical
company known as MSD outside of the United States and Canada, has been
inventing for life, bringing forward medicines and vaccines for many of
the world’s most challenging diseases. Through our prescription
medicines, vaccines, biologic therapies and animal health products, we
work with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies, programs
and partnerships. Today, Merck continues to be at the forefront of
research to advance the prevention and treatment of diseases that
threaten people and communities around the world – including cancer,
cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease
and infectious diseases including HIV and Ebola. For more information,
and connect with us on TwitterFacebookInstagram,
and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may
differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2017 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (

Tracy Ogden, 908-740-1747
Claire Gillespie, 267-305-0932
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

Unsubscribe from email alerts